TAAR1 agonists, including the Phase 3 clinical development candidate ulotaront, have recently emerged as a potential new treatment approach in schizophrenia and other psychiatric disorders including depression, anxiety and substance abuse [1,59,60]. The gene discussed is TAAR1; the disease is depressive disorder.